APR 01, 2017 02:08 PM PDT

First Approved Drug to Show Promise Against Mesothelioma

WRITTEN BY: Xuan Pham

A cancer antibody is showing promising results against mesothelioma, one of the most lethal silent cancers. The antibody is known as pembrolizumab (Keytruda) and works as a second-line immunotherapy agent to destroy the cancer. Researchers say this is the first approved drug to show effectiveness against mesothelioma.

Image: firstwessex.com

As one of the most aggressive cancer types, mesothelioma is a cancer of the lining of the lung. Uniquely, this cancer is caused by exposure to manmade products containing the carcinogen asbestos. When breathed into the lungs, asbestos fibers get trapped and cause scarring and inflammation, triggering serious health conditions like mesothelioma. Though rare nowadays in the US, cases of mesotheliomas are still rampant in other parts of the world due to unregulated use of materials containing asbestos. The disease has a poor prognosis, with less than one-year survival rates after diagnosis.

"There have been a lot of studies looking at different drugs, but researchers have not seen positive results. But we've found this new class of drugs, checkpoint inhibitors, seems to be more effective than what's been available in the past,” said Dr. Evan Alley, a medical oncology specialist at the Penn Presbyterian Medical Center of the University of Pennsylvania Health System in Philadelphia, and the study’s lead author.

In a study of 25 patients with mesothelioma who were given pembrolizumab every 2 weeks for 2 years, the team observed significant changes in cancer progression. This included tumor shrinkage in 14 of the patients. The average survival time was extended to 18 month, of which the first 6 months seem to show no progression of cancer.

"Most patients who receive a second-line therapy have a life expectancy of about 6 or 7 months, so to have four patients still ongoing at 2 years is very encouraging,” said Dr. Alley.

Pembrolizumab targets the programmed cell death 1 (PD-1) receptor, a protein that’s responsible for preventing the immune system from attacking its own cells. Cancers can take advantage of this system by making its own proteins that bind to PD-1, which shuts down the body’s ability to kill the cancer. As an immunotherapy, pembrolizumab boosts the body’s ability to kill the cancer again. The drug is already approved for the treatment of several other types of cancer, including non-small cell lung cancer, melanoma, and some head and neck cancers.

While promising, the results of this study are limited by the small sample size. More validation studies are necessary to confirm the anticancer effects of pembrolizumab against mesothelioma. But as it is, chemotherapy as a first-line defense, and pembrolizumab as a second-line defense seems to be a promising strategy.

“This study provides evidence that some patients can have long-term disease control with this drug, which we haven't seen before. We need to better understand what we can do next to make immunotherapy more effective for more patients,” said Dr. Alley.

Additional sources: MNT

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
AUG 08, 2018
Immunology
AUG 08, 2018
Doxorubicin Causes Heart Toxicity by Immune System Disruption
Chemotherapy drug Doxorubicin disrupts metabolism that controls immune responses in the heart leading to heart toxicity....
AUG 14, 2018
Cancer
AUG 14, 2018
Using Arsenic to Enhance Cancer Therapies Beyond Leukemia
An already existing combination of arsenic and all-trans retinoic acid is found to inhibit a key signaling pathway that exerts broad effect on oncogenic processes for some solid tumors....
SEP 04, 2018
Cancer
SEP 04, 2018
Metal beads that could help reduce chemotherapy side effects in brain tumor
Brain tumors are one of the most challenging types of cancers to treat. Only 1 in 7 patients will survive the disease, and those survivors will usually suffer from lots of side effects becaus...
OCT 30, 2018
Drug Discovery
OCT 30, 2018
Re-sensitizing Drug-resistant Human Tumor Cells
Understanding how cancer cells avoid death despite their DNA being damaged will create new strategies to enhance cancer cell killing through chemotherapy t...
NOV 05, 2018
Videos
NOV 05, 2018
How UV Rays Cause Aging and Skin Cancer
We know that UV rays can do damage to our DNA - but how?...
NOV 26, 2018
Cell & Molecular Biology
NOV 26, 2018
New Insight Into the Machinery That Drives Cell Death
When cells are worn out and damaged or diseased, they can initiate a self-destruct sequence called apoptosis....
Loading Comments...